Skip to main content
. 2018 Mar 8;8(7):185–197. doi: 10.1177/2045125318762365

Table 3.

Outcomes in terms of the amisulpride intervention.

Variable OR or coefficient 95% CI
Primary outcome
>20% reduction in PANSS from baseline (OR) 1.17 (0.40, 3.42)
Secondary outcomes
PANSS negative symptom subscale −0.71 (−3.22, 1.81)
Service engagement: SES 1.17 (−1.63, 3.97)
Depression: CDSS 0.23 (−1.54, 2.00)
Insight: SAI 0.02 (−1.33, 1.37)
Side effects
Non neurological
ANNSERS-E 1.58 (−3.60, 6.76)
Metabolic/endocrine side effects
Weight 0.79 (−1.40, 2.99)
Body mass index −0.02 (−1.05, 1.01)
Waist circumference 1.05 (−2.33, 4.42)
Systolic blood pressure (mmHg) 3.49 (−3.66, 10.63)
Diastolic blood pressure (mmHg) 3.33 (−1.65, 8.31)
Serum prolactin (ng/ml) 50.47 (−8.86, 109.80)
Ln* serum prolactin 1.43 (0.71, 2.14)
Plasma glucose (mmol/liter): nonfasting blood sample 0.66 (−0.22, 1.54)
Total cholesterol (mmol/liter) 0.48 (−0.11, 1.07)
HDL cholesterol (mmol/liter) 0.09 (−0.23, 0.41)
LDL cholesterol (mmol/liter) 0.11 (−0.62, 0.85)
Triglycerides (mmol/liter) 0.78 (−0.10, 1.65)
Motor side effects
BARS: akathisia present$ (global item score ⩾2) (OR) 0.35 (0.06, 2.09)
Tardive dyskinesia: AIMS positive$ (OR) 0.37 (0.03, 4.34)
EPSE −0.04 (−0.22, 0.14)
Parkinsonism present (total score ⩾3)$ (OR) 0.63 (0.18, 2.20)
*

Logarithmic transformation.

$

Unadjusted result, too few events to do an adjusted analysis.

AIMS, Abnormal Involuntary Movement Scale; ANNSERS-E, Antipsychotic Non-Neurological Side Effects Scale enhanced version; BARS, Barnes Akathisia Rating Scale; CDSS, Calgary Depression Rating Scale for Schizophrenia; CI, confidence interval; EPSE, Extrapyramidal Side Effects Scale; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OR, odds ratio, all other results are coefficients; PANSS, Positive and Negative Syndrome Scale; SAI, Schedule for the Assessment of Insight; SES, Service Engagement Scale.